AVKARE Inc. has voluntarily recalled 2,284 cartons of Losartan Potassium Tablets USP (25 mg and 50 mg) after FDA laboratory testing found an impurity called N-Methylnitrosobutyric acid (NMBA) at levels higher than the acceptable daily limit. Losartan Potassium is a prescription medication used to treat high blood pressure and help protect the kidneys from damage due to diabetes. This recall affects unit dose packages distributed nationwide in the United States. Consumers should not stop taking their medication without consulting a healthcare professional first, as the risk of stopping high blood pressure treatment may outweigh the risk of the impurity.
The impurity NMBA is classified as a potential human carcinogen. While the risk of harm from a single dose is low, long-term exposure to levels above the interim acceptable limit of 0.96 parts per million may increase the risk of developing cancer over time.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.